This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Accendra Health, Inc.
11/5/2026
Good evening, and thank you for standing by. Welcome to Ascendra Health's third quarter 2026 earnings conference call. Please be advised that today's conference call is being recorded. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I would now like to hand the conference call over to your first speaker today, Will Parrish, Vice President, Corporate Development and Investor Relations.
Thank you, Operator, and good evening, everyone. I'd like to welcome you to Accendra Health's third quarter earnings call. Our comments on the call will be focused on the financial results of the third quarter of 2026, all of which are included in today's press release. The press release, along with the third quarter 2026 supplemental slides, to which we will refer during the call are posted on the investor relations section of our website. Please note that during this call we will make forward-looking statements that reflect the current views of Ascender Health about our business, financial performance, and future events. Matters addressed in these statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected or implied here today. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that our expectations, beliefs, and projections will result or be achieved. Please refer to our SEC filings for a full description of these risks and uncertainties, including the risk factors section of our annual report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements that we make on this call in our earnings press release or in our supplemental slides are as of today, and we undertake no obligation to update these statements as a result of new information or future events. except to the extent required by applicable law. In our discussion today, we will refer to non-GAAP financial measures and believe they might help investors to better understand our performance or business trends. Information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release. Today, I am joined by Kenny Gardner-Smith, Ascendra Health President and Chief Executive Officer, Jon Leon, the company's Chief Financial Officer, and Scott Lloyd, Company's Chief Commercial Officer. I will now turn the call over to Kenny.
Kenny? Thank you, Will, and good evening to everyone joining us. It is a pleasure to be speaking with you for the first time as CEO. Acindra is home to leading brands that serve important segments of the home DME market. I've had the privilege of serving on the board for the past several years, which gave me a deep appreciation for the clinical importance of what we do and the strength of our brands and footprint. When the opportunity arose to step into the CEO role, I took it because I believe these assets combined with a more disciplined operating system can deliver meaningfully better outcomes for patients, referral sources, and shareholders. My background in growing, optimizing, and scaling specialty healthcare operations and leading turnarounds gives me conviction that most of the issues we face are fixable and largely within our control. I am excited to be here and optimistic about our future. Prior to my official start, I worked closely with the management team and the board on a forward-looking value creation plan. Over the past month, I've spent time digging into the business, listening to leaders and frontline teammates, connecting with key partners, and speaking with our investors. Those conversations, together with the strategy work and the value creation plan, have given myself and the team a clear view of where we stand and what must change. We will not be in a period of prolonged diagnosis. Rather, we are already in the midst of active execution focused on speed to value. I want to acknowledge that in spite of that optimism about our future, we have significantly underperformed expectations in 2026. Before I share my perspective on what has caused the deterioration in performance in 2026 and how we will address it, I will turn it over to John to walk through our Q3 results and balance sheet positioning in more detail.
You're reading a preview of the ACH Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing